Results 251 to 260 of about 17,744 (296)
Some of the next articles are maybe not open access.
Electrophysiology of phosphodiesterase inhibitors
The American Journal of Cardiology, 1989Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
G V, Naccarelli, R A, Goldstein
openaire +2 more sources
Xanthines and Phosphodiesterase Inhibitors
2016Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D, Spina, C P, Page
openaire +2 more sources
Phosphodiesterase inhibitors and the eye
Clinical & Experimental Ophthalmology, 2009AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M, Kerr, Helen V, Danesh-Meyer
openaire +2 more sources
Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors
Chest, 2004To compare the direct pulmonary vasodilating activity and specificity of phosphodiesterase-5 (zaprinast) and phosphodiesterase-3 (milrinone) inhibitors on the pulmonary vascular (PV) bed of the spontaneously breathing cat with an intact chest.Prospective, randomized animal study.Laboratory of university hospital.Experiments were performed in vivo in ...
Idit, Matot, Yaacov, Gozal
openaire +2 more sources
Carboxyamidotriazole: A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases
European Journal of Pharmacology, 2015Carboxyamidotriazole (CAI) is a non-cytotoxic anti-tumor drug, which also shows considerable anti-inflammatory effects in a variety of animal models of inflammation. The exact target and mechanism of CAI were not clearly understood yet. In the present study, we demonstrate that CAI is a non-selective phosphodiesterase (PDE) inhibitor, which provides ...
Lei Guo +8 more
openaire +2 more sources
Cyclic nucleotide phosphodiesterases
Journal of Allergy and Clinical Immunology, 2001Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led
openaire +2 more sources
Phosphodiesterase-5 Inhibitors
2013Nitric oxide (NO) signaling plays a key role in modulating vascular tone and remodeling in the pulmonary circulation. The guanylate cyclase/cyclic guanylate monophosphate-signaling pathway primarily mediates nitric oxide signaling. This pathway is critical in normal regulation of the pulmonary vasculature, and is an important target for therapy in ...
Barbara A, Cockrill, Aaron B, Waxman
openaire +2 more sources
Tyrosyl‐DNA Phosphodiesterase (Tdp1) (3′‐Phosphotyrosyl DNA Phosphodiesterase)
2006Tyrosyl-DNA phosphodiesterase (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds in vitro. Because topoisomerase I, a type IB topoisomerase, is the only enzyme known to form 3'-phosphotyrosine bonds in eukaryotic cells, it was proposed that Tdp1 is involved in the repair of dead-end topoisomerase I-DNA covalent complexes that may form in vivo.
Amy C, Raymond, Alex B, Burgin
openaire +2 more sources